Liminatus Pharma Reports Improved Net Loss and Significant Business Changes in Latest 10-Q

Liminatus Pharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company, which specializes in developing immune-modulating cancer therapies, recorded a net loss of $2.04 million for the nine months ended September 30, 2025, a 39% improvement compared to a net loss of $3.32 million during the same period in 2024. The loss from operations for the nine months was $2.08 million, down from $3.16 million in the prior year. The company did not generate any revenue during either period, highlighting its reliance on future product development for financial viability.

In terms of operational changes, Liminatus Pharma underwent a significant business combination with Iris Acquisition Corp on April 30, 2025, which resulted in a recapitalization and a name change from Iris Parent Holding Corp. The transaction included the conversion of $14.8 million in related party debt into common stock, which contributed to a substantial increase in the company's equity base. As of September 30, 2025, the company had 27,064,633 shares of common stock outstanding, up from 17,500,000 shares at the end of 2024.

The company’s financial position showed a marked decrease in total assets, which fell to $1.34 million from $5.41 million at the end of 2024. This decline was primarily due to the elimination of loan receivables and deferred transaction costs associated with the business combination. Current liabilities also decreased significantly, from $24.75 million to $2.99 million, reflecting the settlement of various debts and obligations during the merger process. However, Liminatus reported an accumulated deficit of $30.70 million as of September 30, 2025, indicating ongoing financial challenges.

Liminatus Pharma's operational metrics revealed a shift in focus, with general and administrative expenses rising sharply to $2.08 million for the nine months ended September 30, 2025, compared to $477,542 in the prior year. This increase is attributed to higher costs associated with operating as a publicly traded company, including legal and accounting fees. Research and development expenses were eliminated following the termination of a license agreement with Targeted Diagnostics & Therapeutics, which had previously accounted for significant expenditures.

Looking ahead, Liminatus Pharma faces substantial uncertainty regarding its ability to continue as a going concern. The company has expressed doubts about its capacity to raise sufficient capital to fund operations, which may necessitate reevaluating future business strategies. Management plans to pursue additional financing through equity and debt arrangements, although there is no assurance that these efforts will be successful. The company’s ability to develop its intellectual property into commercially viable products remains critical for its long-term sustainability.